181 related articles for article (PubMed ID: 2844304)
21. Effects of vasoactive intestinal peptide on adenosine 3',5'-monophosphate, ornithine decarboxylase, and cell growth in a human colon cell line.
Yu D; Seitz PK; Selvanayagam P; Rajaraman S; Townsend CM; Cooper CW
Endocrinology; 1992 Sep; 131(3):1188-94. PubMed ID: 1324153
[TBL] [Abstract][Full Text] [Related]
22. Molecular identification of receptors for vasoactive intestinal peptide in rat intestinal epithelium by covalent cross-linking. Evidence for two classes of binding sites with different structural and functional properties.
Laburthe M; Breant B; Rouyer-Fessard C
Eur J Biochem; 1984 Feb; 139(1):181-7. PubMed ID: 6321173
[TBL] [Abstract][Full Text] [Related]
23. Characterization of the vasoactive intestinal peptide (VIP) binding sites: a biochemical and an immunological approach.
Marvaldi J; Luis J; Muller JM; el Battari A; Fantini J; Martin JM; Abadie B; Tirard A; Pichon J
Peptides; 1986; 7 Suppl 1():137-45. PubMed ID: 3018691
[TBL] [Abstract][Full Text] [Related]
24. A human melanoma-derived cell line (IGR39) with a very high number of vasoactive-intestinal-peptide (VIP) receptors. 2. Effect of VIP on cAMP production and on cell-surface VIP-binding sites.
Martin JM; Luis J; Marvaldi J; Pichon J; Pic P
Eur J Biochem; 1989 Mar; 180(2):435-9. PubMed ID: 2538331
[TBL] [Abstract][Full Text] [Related]
25. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
26. Solubilization of the liver vasoactive intestinal peptide receptor. Hydrodynamic characterization and evidence for an association with a functional GTP regulatory protein.
Couvineau A; Amiranoff B; Laburthe M
J Biol Chem; 1986 Nov; 261(31):14482-9. PubMed ID: 3021741
[TBL] [Abstract][Full Text] [Related]
27. Molecular characteristics and peptide specificity of vasoactive intestinal peptide receptors from rat cerebral cortex.
Couvineau A; Gammeltoft S; Laburthe M
J Neurochem; 1986 Nov; 47(5):1469-75. PubMed ID: 3020175
[TBL] [Abstract][Full Text] [Related]
28. Interaction of vasoactive intestinal peptide with a cell line (HeLa) derived from human carcinoma of the cervix: binding to specific sites and stimulation of adenylate cyclase.
Prieto JC; Guerrero JM; de Miguel C; Goberna R
Mol Cell Biochem; 1981 Jul; 37(3):167-76. PubMed ID: 6268963
[TBL] [Abstract][Full Text] [Related]
29. Identification of nuclear receptors for VIP on a human colonic adenocarcinoma cell line.
Omary MB; Kagnoff MF
Science; 1987 Dec; 238(4833):1578-81. PubMed ID: 2825352
[TBL] [Abstract][Full Text] [Related]
30. Vasoactive intestinal peptide receptor on liver plasma membranes: solubilization and cross-linking.
Nguyen TD; Kaiser LM
Peptides; 1990; 11(6):1255-61. PubMed ID: 1965036
[TBL] [Abstract][Full Text] [Related]
31. Photoaffinity labelling of the vasoactive-intestinal-peptide-binding site on intact human colonic adenocarcinoma cell line HT29-D4. Synthesis and use of photosensitive vasoactive-intestinal-peptide derivatives.
Martin JM; Darbon H; Luis J; el Battari A; Marvaldi J; Pichon J
Biochem J; 1988 Mar; 250(3):679-85. PubMed ID: 2839143
[TBL] [Abstract][Full Text] [Related]
32. Vasoactive intestinal peptide and intraocular pressure: adenylate cyclase activation and binding sites for vasoactive intestinal peptide in membranes of ocular ciliary processes.
Mittag TW; Tormay A; Podos SM
J Pharmacol Exp Ther; 1987 Apr; 241(1):230-5. PubMed ID: 3033201
[TBL] [Abstract][Full Text] [Related]
33. Purification of vasoactive intestinal peptide receptor from porcine liver by a newly designed one-step affinity chromatography.
Couvineau A; Voisin T; Guijarro L; Laburthe M
J Biol Chem; 1990 Aug; 265(22):13386-90. PubMed ID: 2165502
[TBL] [Abstract][Full Text] [Related]
34. Phorbol ester induces loss of VIP stimulation of adenylate cyclase and VIP-binding sites in HT29 cells.
Bozou JC; Couvineau A; Rouyer-Fessard C; Laburthe M; Vincent JP; Kitabgi P
FEBS Lett; 1987 Jan; 211(2):151-4. PubMed ID: 3026847
[TBL] [Abstract][Full Text] [Related]
35. A human melanoma-derived cell line (IGR39) with a very high number of vasoactive-intestinal-peptide (VIP) receptors. 1. Molecular characterization of the binding site.
Luis J; Martin JM; el Battari A; Reynier M; Marvaldi J; Pichon J
Eur J Biochem; 1989 Mar; 180(2):429-33. PubMed ID: 2538330
[TBL] [Abstract][Full Text] [Related]
36. Cloning and expression of the human vasoactive intestinal peptide receptor.
Sreedharan SP; Robichon A; Peterson KE; Goetzl EJ
Proc Natl Acad Sci U S A; 1991 Jun; 88(11):4986-90. PubMed ID: 1675791
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological characterization of the novel helodermin/VIP receptor present in human SUP-T1 lymphoma cell membranes.
Robberecht P; De Neef P; Gourlet P; Cauvin A; Coy DH; Christophe J
Regul Pept; 1989; 26(2):117-26. PubMed ID: 2552509
[TBL] [Abstract][Full Text] [Related]
38. Evidence for vasoactive intestinal peptide receptors in apical membranes from tracheal epithelium.
Elgavish A; Pillion DJ; Meezan E
Life Sci; 1989; 44(15):1037-42. PubMed ID: 2538697
[TBL] [Abstract][Full Text] [Related]
39. The vasoactive intestinal peptide (VIP) receptor: recent data and hypothesis.
Luis J; Martin JM; el Battari A; Marvaldi J; Pichon J
Biochimie; 1988 Oct; 70(10):1311-22. PubMed ID: 2852963
[TBL] [Abstract][Full Text] [Related]
40. Hormone-specific combinations of isoforms of adenylyl cyclase and phosphodiesterase in the rat liver.
Yamatani K; Saito K; Takahashi K; Ohnuma H; Manaka H; Sasaki H
Regul Pept; 2001 May; 99(1):45-52. PubMed ID: 11257314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
